Low-dose contrast-enhanced magnetic resonance imaging of brain metastases at 3.0T using high-relaxivity contrast agents

Background: Lesion-to-brain contrast after gadolinium administration is significantly higher at 3.0 Tesla (T) compared to 1.5T. The high in vivo relaxivity of gadobenate dimeglumine (Gd-BOPTA) may permit the use of lower-dose contrast agents. Purpose: To investigate whether low-dose contrast-enhance...

Full description

Saved in:
Bibliographic Details
Published in:Acta radiologica (1987) 2010-02, Vol.51 (1), p.78-84
Main Authors: Huang, Biao, Liang, Chang-Hong, Liu, Hong-Jun, Wang, Guang-Yi, Zhang, Shui-Xing
Format: Article
Language:English
Subjects:
Biological and medical sciences
Medical sciences
Neurology
Tumors of the nervous system. Phacomatoses
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: Lesion-to-brain contrast after gadolinium administration is significantly higher at 3.0 Tesla (T) compared to 1.5T. The high in vivo relaxivity of gadobenate dimeglumine (Gd-BOPTA) may permit the use of lower-dose contrast agents. Purpose: To investigate whether low-dose contrast-enhanced MRI at 3.0T using a high-relaxivity contrast agent (Gd-BOPTA) can achieve a comparable or improved contrast-to-noise ratio (CNR) for the detection of brain metastases compared with examination of the same patient at 1.5T using a standard dose of gadopentetate dimeglumine (Gd-DTPA). Material and Methods: A total of 18 patients with known brain metastases were first imaged at 1.5T with 0.1 mmol/kg Gd-DTPA. Patients returned at least 24 hours later for imaging at 3.0T with Gd-BOPTA at cumulative doses of 0.025 mmol/kg, 0.05 mmol/kg, 0.075 mmol/kg, and 0.1 mmol/kg (0.1 mmol/kg body weight overall). The CNR of enhancing brain lesions compared to the normal contralateral white matter was calculated. For the 3.0T study using different cumulative doses of Gd-BOPTA, the CNR of lesions was compared with CNR of the same lesions imaged at 1.5T using 0.1 mmol/kg Gd-DTPA, by using the Wilcoxon matched-pairs signed-rank test. Results: At 1.5T with 0.1 mmol/kg Gd-DTPA, the mean CNR between enhanced lesions and cerebral white matter was 12.01 ± 2.53. With 3.0T imaging using different cumulative doses of Gd-BOPTA, the mean CNRs were 7.19 ± 4.06, 15.31 ± 6.37, 25.44 ± 11.02, and 31.88 ± 13.21. At 3.0T with 0.05 mmol/kg Gd-BOPTA, CNR was 1.34-fold higher compared to CNR at 1.5T with 0.1 mmol/kg Gd-DTPA (P
ISSN:0284-1851
1600-0455
DOI:10.3109/02841850903350178